
NCCN guidelines indicate rusfertide for patients who are intolerant to phlebotomy or who receive frequent phlebotomy, regardless of risk status.
JAK Inhibition for the Management of Primary Myelofibrosis
Case: 66-Year-Old Man Diagnosed With Primary Myelofibrosis
January 2019

